Ali Rezai, MD

Ali Rezai, MD, is the executive chair of the Rockefeller Neuroscience Institute, associate dean of Neuroscience and the John D. Rockefeller IV Chair at West Virginia University. A neuroscientist and practicing neurosurgeon, Dr. Rezai’s clinical areas of expertise include the neurosurgical management of Parkinson’s disease, chronic pain, and behavioral disorders. His work at the Institute also targets important societal health challenges such as Alzheimer’s disease and addiction.

Dr. Rezai has led teams that have pioneered groundbreaking techniques and treatments such as neuromodulation and brain implants to treat traumatic brain and spinal cord injury, headaches, Alzheimer’s, and other neurological disorders. His work has been widely recognized: the brain-computer interface to treat paralysis was published in the Journal Nature in 2016 and also generated front-page news in the New York Times, The Wall Street Journal, and The Financial Times. Recently the Rockefeller Neuroscience Institute team and its partners conducted the first phase II human trial to treat early-stage Alzheimer’s disease using an innovative focused ultrasound technology.

Dr. Rezai has authored more than 220 scientific publications, has received several awards for innovation, and currently holds 55 US patents. His research in neuromodulation has led to novel therapeutic applications and medical device technology. He has trained more than 50 fellows and presented findings in neuroscience and brain health to the President of the United States and the United States Congress.

WVU Medicine © 2019

Ben Leedle

President & CEO and Board Director, Blue Zones

Ben R. Leedle, Jr., is a transformative business leader who envisions and creates world-class companies. He has spent his career building and delivering value-based businesses established and grown on the fundamental proposition that healthier people cost less and perform better. He is broadly recognized as the visionary and driving force behind transforming Healthways, Inc. from a small company focused on diabetes treatment to the number one independent population health management and well-being improvement company in the world. Among his collaborative accomplishments during his tenure as CEO, Mr. Leedle co-founded both, the Blue Zones Project and the Gallup-Healthways Well-Being Index innovations.

He is also actively engaged as strategic advisor/chairman and/or board director/investor for several companies including BeHealth Solutions, a digital therapeutics company, Equality Health, a health plan and care system for disparate populations, Health Velocity Capital, a health technology and services innovation partner to entrepreneurs and investors, Synchronous Health, an Artificial Intelligence + clinician service model for addressing the top 10 behavioral health diagnoses and Diversicare (NASDAQ: DVCR), a large provider of long-term care services

Ben Leedle

President & CEO and Board Director, Blue Zones

Ben R. Leedle, Jr., is a transformative business leader who envisions and creates world-class companies. He has spent his career building and delivering value-based businesses established and grown on the fundamental proposition that healthier people cost less and perform better. He is broadly recognized as the visionary and driving force behind transforming Healthways, Inc. from a small company focused on diabetes treatment to the number one independent population health management and well-being improvement company in the world. Among his collaborative accomplishments during his tenure as CEO, Mr. Leedle co-founded both, the Blue Zones Project and the Gallup-Healthways Well-Being Index innovations.

He is also actively engaged as strategic advisor/chairman and/or board director/investor for several companies including BeHealth Solutions, a digital therapeutics company, Equality Health, a health plan and care system for disparate populations, Health Velocity Capital, a health technology and services innovation partner to entrepreneurs and investors, Synchronous Health, an Artificial Intelligence + clinician service model for addressing the top 10 behavioral health diagnoses and Diversicare (NASDAQ: DVCR), a large provider of long-term care services